

<sup>1</sup>Bioengineering & Bioinformatics Summer Institute, Dept. of Computational Biology, University of Pittsburgh, 15260 <sup>2</sup>Department of Chemistry, Grambling State University, Grambling, LA 71245 <sup>3</sup>Departments of Pharmaceutical Sciences and of Chemistry, University of Pittsburgh, Pittsburgh, PA 15261

## Abstract

Microtubule stabilization is a validated mechanism for cancer chemotherapy. Dictyostatin, an analog of the failed drug discodermolide, binds to the  $\beta$ -tubulin subunit of microtubules, inhibiting cell growth by blockage at the G2/M phase of the cell cycle. Dictyostatin and analogs were synthesized and their antiproliferative activities against ovarian cancer cells were measured. These data, along with that from some discodermolides, were used to determine a quantitative structure-activity relationship (QSAR). Molecular models of the dictyostatins were built from NMR coordinates of discodermolide and their global minimum energy conformations determined. Models were superimposed to provide maximum structural overlap and a collection of electronic, thermodynamic and steric descriptors were calculated for each model. A special multiple linear regression analysis, the genetic function approximation, was then used to find the descriptors that best explained the differences in activity. A population of statistically-compelling QSAR equations was found and these may be useful in future analog design.

# Background

The discovery and advancement of new chemotherapeutic agents for the treatment of cancer is currently of high significance. Some of the most useful chemotherapeutic agents are natural products or natural product analogs. For example, paclitaxel is a natural product that is currently being used to treat patients with breast, lung and ovarian cancers. Paclitaxel belongs to a group of chemicals known as taxanes, which functions through binding to the  $\beta$ -tubulin subunits of microtubules. A number of analogs of paclitaxel, including docetaxel, are also clinically useful anticancer agents.

The mechanism by which paclitaxel hinders cancer cell growth is the stabilization of microtubules. Microtubules are polymers made up of  $\alpha$ - and  $\beta$ -tubulin heterodimers. Tubulin polymerizes at each end with the  $\alpha$ -subunit of one tubulin dimer connecting to the  $\beta$ -subunit of the next. Therefore, one end of the microtubule will have the  $\alpha$ -subunit (minus or – end, where microtubule shrinking can occur) exposed, while the other end will have the  $\beta$ -subunit (plus, +, or growing end) exposed.

The  $\alpha$ - and  $\beta$ -tubulin subunits each bind one mole of guanosine triphosphate (GTP). The GTP bound to  $\alpha$ -tubulin is stable, but the GTP bound to  $\beta$ -tubulin can be hydrolyzed to guanosine diphosphate (GDP) shortly after a heterodimer adds to the growing polymer. The GTPbound  $\beta$ -tubulin therefore forms a cap at the (+) end of the microtubule, keeping it from disassembling. When hydrolysis catches up to the tip of the microtubule, it begins to quickly depolymerize and shrink. GTPbound tubulin can begin adding to the tip of the microtubule again, providing a new cap and protecting the microtubule from shrinking. However, when a drug such as the taxanes is attached, it hyperstabilizes microtubules by binding to the  $\beta$ -tubulin of the microtubule and preventing the disassembly from the (-) end.

Like paclitaxel, discodermolide, a polyketide natural product, was discovered to be a very potent inhibitor of cancer cell growth. It has been proven to inhibit the growth of human cells by blocking them at G2/ M phase of the cell cycle. It was a clinical candidate for cancer chemotherapy due to its high potency in microtubule stabilization and its strong activity against multiple drug resistant cancers. Unfortunately, discodermolide only made it to Phase II clinical trials when tested in humans, where it failed due to unexpected toxicity.

Because discodermolide showed promising effects, it was important in the fields of chemotherapy and drug discovery to uncover an agent quite similar in structure and activity. It was determined that another marine sponge-derived natural product discovered in 1994, dictyostatin, shares much structural similarity to discodermolide, including identical configurations at all common stereocenters. Dictyostatin also has very similar biological activity to discodermolide. It is active against paclitaxel-resistant cell lines and is one of the most potent microtubule stabilizers known, potently competing with paclitaxel and discodermolide for the taxoid binding site on microtubules. With the recent withdrawal of discodermolide from clinical development, the importance of uncovering a dictyostatin with the potential for clinical development has increased. Several analogs of dictyostatin have been synthesized and some of their biological activities have been measured. Using the structures of these analogs and their biological activities, along with those of discodermolide and a potent, structurally-related analog, the purpose of this work will be to develop a quantitative structure-activity relationship (QSAR) useful in further analog design.







and  $\triangle$  of 17 without "HF\_MOPAC".





